NCT01881048View on ClinicalTrials.gov

Window of Opportunity Study Targeting the Inflammatory Milieu

EARLY_PHASE1Active, not recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

December 8, 2009

Primary Completion Date

January 14, 2014

Study Completion Date

December 31, 2025

Conditions
Stage IA Breast CancerStage IB Breast CancerStage II Breast CancerStage IIIA Breast CancerStage IIIB Breast CancerStage IIIC Breast CancerStage IV Breast Cancer
Interventions
DIETARY_SUPPLEMENT

Omega-3 fatty acid

Given PO

DRUG

Celecoxib

Given PO

Trial Locations (1)

80045

University of Colorado Cancer Center, Aurora

All Listed Sponsors
lead

University of Colorado, Denver

OTHER